Skip to main content

Advertisement

Table 2 Constituents of commercially available PCCs in Europe (based on product labeling*)

From: Bench-to-bedside review: Optimising emergency reversal of vitamin K antagonists in severe haemorrhage – from theory to practice

  Factor content Antithrombotic content
  II VII IX X Protein C, S, Z (label IU/ml)   
Product (manufacturer); international availability Label IU/ml Ratio Label IU/ml Ratio Label IU/ml Ratio Label IU/ml Ratio C S Z ATIII (label IU/ml) Heparin (label IU/ml)
Beriplex P/N (CSL Behring); major western European countries 20–48 133% 10–25 69% 20–31 100% 22–60 161% 15–45 13–26 Not in label 0.2–1.5 0.4–2.0
Octaplex (Octapharma); major western European countries 11–38 98% 9–24 66% 25 100% 18–30 96% 7–31 7–32 Not in label Not in label Not in label
Prothromplex Total/S-TIM 4 Immuno (Baxter); Sweden, Germany, Austria 30 100% 25 83% 30 100% 30 100% >20 Not in label Not in label 0.75–1.5 <15
Prothromplex TIM 3 (Baxter); Italy, Austria 25 100% Not in label - 25 100% 25 100% Not in label Not in label Not in label Not in label 3.75
Cofact/PPSB SD (Sanquin/CAF); Netherlands, Belgium, Austria, Germany ≥ 15 75% ≥ 5 25% ≥ 20 100% ≥ 15 75% Not in label Not in label Not in label Present, not quantified Not in label
Kaskadil (LFB); France 40 160% 25 100% 25 100% 40 160% Not in label Not in label Not in label Not in label Present, not quantified
Uman Complex DI (Kedrion); Italy 25 100% Not in label 0% 25 100% 20 80% Not in label Not in label Not in label Present, not quantified Present, not quantified
PPSB-human SD/Nano (Octapharma); Germany 25–55 130% 7.5–20 45% 24–37.5 100% 25–55 130% 20–50 5–25 Not in label 0.5–3 0.5–6
  1. Factor content ratios are based on the content of factor IX [27]. *In Europe, ranges are usually given on the product label, in accordance with the European Pharmacopoeia; single values are generally from older, national registrations. ATIII, antithrombin III; PCC, prothrombin complex concentrate. Reproduced from Levy et al. Perioperative hemostatic management of patients treated with vitamin K antagonists [27]. Reproduced with permission from Lippincott Williams & Wilkins (http://www.lww.com/)